Differential expression of E-cadherin in primary breast cancer and corresponding lymph node metastases

Anticancer Research

Volumn 35, Issue 2, 2015, Pages 759-765

  Fulga, Veaceslav ^a   Rudico, Lucian ^a   Balica, Amalia Raluca ^b   Cimpean, Anca Maria ^b   Saptefrati, Lilian ^a   Margan, Madalin Marius ^b   Raica, Marius ^b  

^a STATE UNIVERSITY OF MEDICINE AND PHARMACY NICOLAE TESTEMITANU   (Moldova)

^b VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Breast cancer; Invasive carcinoma NST type; Metastasis; Molecular subtypes

Indexed keywords

CADHERIN; TUMOR MARKER;

BREAST TUMOR; FEMALE; HUMAN; LYMPH NODE METASTASIS; METABOLISM; PATHOLOGY;

BREAST NEOPLASMS; CADHERINS; FEMALE; HUMANS; LYMPHATIC METASTASIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84923673777     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. van Roy F and Berx G: The cell-cell adhesion molecule Ecadherin. Cell Mol Life Sci 65: 3756-3788, 2008.
2. Takeichi M: Cadherins: a molecular family important in selective cell-cell adhesion. Annu Rev Biochem 59: 237-252, 1990.
3. Bracke ME, Von Roy FM and Mareel MM: The Ecadherin/ catenin complex in invasion and metastasis. Curr Top Microbiol Immunol 213: 123-161, 1996.
4. Larue L, Ohsugi M, Hirchenhain J and Kemler R: E-cadherin null mutant embryos fail to form a trophectoderm epithelium. PRoc Natl Acad Sci USA 91: 8263-8267, 1994.
5. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Löchner D and Birchmeier W: E-Cadherin mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113: 173-185, 1991.
6. Berx G and Van Roy F: The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 3: 289-293, 2001.
7. Radisky DC: Epithelial-mesenchymal transition. J Cell Sci 118: 4325-4326, 2005.
8. Derksen PW, Braumuller TM, van der Burg E, Hornsveld M, Mesman E, Wesseling J, Krimpenfort P and Jonkers J: Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice. Dis Model Mech 4(3): 347-358, 2011.
9. Kowalski P, Rubin M and Kleer C: E-Cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 5: R217-R222, 2003.
10. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO and Botstein D: Molecular portraits of human breast tumours. Nature 406( 6797): 747-752, 2000.
11. Chekhun S, Bezdenezhnykh N, Shvets J and Lukianova N: Expression of biomarkers related to cell adhesion, metastasis and invasion of breast cancer cell lines of different molecular subtype. Exp Oncol 35(3): 174-179, 2013.
12. Tang D, Xu S, Zhang Q and Zhao W: The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Med Oncol 29(2): 526-533, 2012.
13. Ionescu Popescu C, Giuşcə SE, Liliac L, Avadanei R, Ceauşu R, ɤmpean AM, Balan R, Aməlinei C, Ciobanu Apostol D and Čruntu ID: E-Cadherin expression in molecular types of breast carcinoma. Rom J Morphol Embryol 54: 267-73, 2013.
14. Chu K, Boley KM, Moraes R, Barsky SH and Robertson FM: The paradox of E-cadherin: role in response to hypoxia in the tumor microenvironment and regulation of energy metabolism. Oncotarget 4( 3): 446-62, 2013.
15. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, PRess MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical Oncology and College of American Pathologists: Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol 31( 31): 3997-4013, 2013.
16. Azoulay S, Laé M, Fréneaux P, Merle S, Al Ghuzlan A, Chnecker C, Rosty C, Klijanienko J, Sigal-Zafrani B, Salmon R, Fourquet A, Sastre-Garau X and Vincent-Salomon A: KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod Pathol 18: 1623-31, 2005.
17. Qureshi HS, Linden MD, Divine G and Raju UB: E-Cadherin status in breast cancer correlates with histologic type but does not correlate with established prognostic parameters. Am J Clin Pathol 125(3): 377-85, 2006.
18. Evans JD: Straightforward statistics for the behavioral sciences, Pacific Grove, CA: Brooks/Cole Publishing, 1996.
19. Moll R, Mitze M, Frixen UH and Birchmeier W: Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol 143: 1731-1742, 1993.
20. Acs G, Lawton TJ, Rebbeck TR, LiVolsi VA and Zhang PJ: Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol 115: 85-98, 2001.
21. Goldstein NS: Does the level of E-cadherin expression correlate with the primary breast carcinoma infiltration pattern and type of systemic metastasis? Am J Clin Pathol 118: 425-434, 2002.
22. Chao YL, Shepard CR and Wells A: Breast carcinoma cells reexpress E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer 9: 179, 2010.
23. Hollestelle A, Peeters JK, Smid M, Timmermans M, Verhoog LC, Westenend PJ, Heine AA, Chan A, Sieuwerts AM, Wiemer EA, Klijn JG, van der Spek PJ, Foekens JA, Schutte M, den Bakker MA and Martens JW: Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer. Breast Cancer Res Treat 138: 47-57, 2013.
24. Gould Rothberg BE and Bracken MB: E-cadherin immuno-histochemical expression as a prognostic factor in infiltrating ductal carcinoma of the breast: a systematic review and meta-analysis. Breast Cancer Res Treat 100(2): 139-148, 2006.
25. Falck AK, Bendahl PO, Chebil G, Olsson H, Fernö M and Ryden L: Biomarker expression and St Gallen molecular subtype classi fication in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up. Breast cancer Res Treat 140(1): 93-104, 2013.
26. Bertolo C, Guerrero D, Vicente F, Cordoba A, Esteller M, Ropero S, Guillen-Grima F, Martinez-Peñuela JM and Lera JM: Differences and molecular immunohistochemical parameters in the subtypes of infiltrating ductal breast cancer. Am J Clin Pathol 130(3): 414-24, 2008.